PL3697819T3 - Leczenie nowotworu złośliwego jajnika anty-cd47 i anty-pd-l1 - Google Patents

Leczenie nowotworu złośliwego jajnika anty-cd47 i anty-pd-l1

Info

Publication number
PL3697819T3
PL3697819T3 PL18807145.0T PL18807145T PL3697819T3 PL 3697819 T3 PL3697819 T3 PL 3697819T3 PL 18807145 T PL18807145 T PL 18807145T PL 3697819 T3 PL3697819 T3 PL 3697819T3
Authority
PL
Poland
Prior art keywords
treatment
ovarian cancer
ovarian
cancer
Prior art date
Application number
PL18807145.0T
Other languages
English (en)
Inventor
Chris Hidemi Mizufune TAKIMOTO
Jens-Peter VOLKMER
Mark Ping Chao
Original Assignee
Forty Seven, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty Seven, Inc. filed Critical Forty Seven, Inc.
Publication of PL3697819T3 publication Critical patent/PL3697819T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL18807145.0T 2017-10-18 2018-10-18 Leczenie nowotworu złośliwego jajnika anty-cd47 i anty-pd-l1 PL3697819T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574073P 2017-10-18 2017-10-18
PCT/US2018/056442 WO2019079549A1 (en) 2017-10-18 2018-10-18 TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1

Publications (1)

Publication Number Publication Date
PL3697819T3 true PL3697819T3 (pl) 2023-03-06

Family

ID=64402251

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18807145.0T PL3697819T3 (pl) 2017-10-18 2018-10-18 Leczenie nowotworu złośliwego jajnika anty-cd47 i anty-pd-l1

Country Status (12)

Country Link
US (1) US20210047416A1 (pl)
EP (2) EP4194470A1 (pl)
JP (3) JP7308190B2 (pl)
KR (1) KR20200070341A (pl)
CN (1) CN111315783A (pl)
AU (1) AU2018351007B2 (pl)
CA (1) CA3078430A1 (pl)
ES (1) ES2938652T3 (pl)
PL (1) PL3697819T3 (pl)
PT (1) PT3697819T (pl)
SI (1) SI3697819T1 (pl)
WO (1) WO2019079549A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011097C (en) 2016-01-11 2022-12-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
PL4177270T3 (pl) 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
EP3752190B1 (en) 2018-02-12 2022-07-06 Forty Seven, Inc. Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
CN113825774B (zh) * 2019-05-17 2024-07-30 南京金斯瑞生物科技有限公司 抗cd47/抗pd-l1多抗原结合蛋白及其使用方法
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
CN120437288A (zh) * 2019-12-24 2025-08-08 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
WO2021170082A1 (zh) * 2020-02-28 2021-09-02 南京圣和药业股份有限公司 抗cd47/抗pd-l1抗体及其应用
KR20230129482A (ko) * 2021-01-08 2023-09-08 베이징 한미 파마슈티컬 컴퍼니 리미티드 항pd-l1/항cd47 천연항체 구조 형태의 헤테로다이머이중특이성 항체 및 그 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
CN105189556A (zh) 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
PL3204018T3 (pl) * 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
CN116425875A (zh) * 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
WO2017117196A1 (en) * 2015-12-28 2017-07-06 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
AU2017210224B2 (en) * 2016-01-21 2024-02-08 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Also Published As

Publication number Publication date
JP7474827B2 (ja) 2024-04-25
CN111315783A (zh) 2020-06-19
JP7308190B2 (ja) 2023-07-13
WO2019079549A1 (en) 2019-04-25
EP4194470A1 (en) 2023-06-14
US20210047416A1 (en) 2021-02-18
ES2938652T3 (es) 2023-04-13
KR20200070341A (ko) 2020-06-17
JP2023014162A (ja) 2023-01-26
EP3697819A1 (en) 2020-08-26
CA3078430A1 (en) 2019-04-25
AU2018351007A1 (en) 2020-05-21
EP3697819B1 (en) 2022-11-16
SI3697819T1 (sl) 2023-01-31
JP2024024121A (ja) 2024-02-21
PT3697819T (pt) 2023-02-20
JP2021500336A (ja) 2021-01-07
AU2018351007B2 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL263925A (en) Methods of treating ovarian cancer
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
PT3697819T (pt) Tratamento de cancro do ovário com anti-cd47 e anti-pd-l1
IL261959B1 (en) Cancer treatment with tg02
EP3157336A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
ZA201802481B (en) Novel biomarkers and methods of treating cancer
IL262342A (en) Cancer treatment methods
HUE051059T2 (hu) Rák és diabétesz kezelésére szolgáló 6-heterociklusos-4-morfolin-4-ilpiridin-2-on vegyületek
SG11202005163PA (en) Methods of treating cancer
SG10202103525UA (en) Cancer biomarkers and methods of use
IL269123A (en) Methods of treating cancer
GB201503371D0 (en) Methods of screening and treatment
IL255541A (en) Cabazitaxel and its use for treating cancer
GB201609402D0 (en) Materials and methods for treating cancer
SG11202002529TA (en) Ovarian cancer biomarker and use thereof
GB201704287D0 (en) Treatment of cancer
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer
GB201702139D0 (en) Methods of cancer treatment
AU2016904962A0 (en) Methods of treating cancer and reagents therefor
GB201522615D0 (en) Methods of screening and treatment
GB201505437D0 (en) Methods of screening and treatment